Hospital
Appalachian Regional Healthcare, INC.
Appalachian Regional Healthcare, INC. was paid $17.87M by Medicaid between Jan 2018 and Dec 2024, across 152 billing codes. Its largest line is 99284, emergency room visit (serious) — 23% of everything it billed.
33Billing provider infoAPPALACHIAN REGIONAL HEALTHCARE, INC.
WEST LIBERTY, KY 41472
WEST LIBERTY, KY 41472
33aNPI1356367270assigned 07/14/2006
33bProvider typeCritical Access Hospital
28Total paid$17.87M
24GClaims364,673
24DCodes billed152
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Kentucky
Rank by total paid#6 of 16
Median peer was paid$11.73M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HARRIS, HOLLIE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 58,421 | $2.86M | |
| 2019 | 51,535 | $2.49M | |
| 2020 | 47,846 | $2.43M | |
| 2021 | 58,642 | $2.71M | |
| 2022 | 56,676 | $2.59M | |
| 2023 | 50,271 | $2.49M | |
| 2024incomplete | 41,282 | $2.30M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 23% | 8,796 | 7,137 | $4.19M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 8.5% | 2,249 | 1,938 | $1.53M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.4% | 2,739 | 2,070 | $1.51M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.3% | 12,761 | 11,263 | $1.30M |
| 80053 | Comprehensive metabolic panel | 3.7% | 27,144 | 18,745 | $666K |
| 36415 | Collection of venous blood by venipuncture | 2.6% | 78,598 | 27,274 | $463K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 2.3% | 664 | 428 | $406K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.3% | 8,317 | 5,986 | $404K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 1,396 | 1,116 | $363K |
| 87631 | 2.0% | 3,546 | 3,254 | $357K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 24,130 | 19,047 | $311K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 4,131 | 3,717 | $296K |
140 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.6% | 6,920 | $291K |
| G0378 | Hospital observation service, per hour | 1.5% | 1,002 | $271K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.4% | 4,185 | $254K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 4,500 | $246K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.3% | 3,661 | $231K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 4,661 | $205K |
| 84484 | 1.1% | 4,953 | $202K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 3,793 | $198K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 227 | $189K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 3,544 | $185K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.0% | 4,541 | $183K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,189 | $164K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,513 | $159K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,584 | $155K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,965 | $148K |
| 87040 | <1% | 2,771 | $145K | |
| 82607 | <1% | 5,379 | $129K | |
| 80061 | Lipid panel | <1% | 6,659 | $127K |
| 81001 | <1% | 10,197 | $116K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,710 | $115K |
| 84145 | <1% | 1,618 | $115K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,459 | $95K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,609 | $89K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,081 | $86K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,340 | $83K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,368 | $83K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,715 | $76K |
| 83735 | <1% | 8,476 | $72K | |
| 83605 | <1% | 2,544 | $70K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,058 | $69K |
| 82553 | <1% | 2,218 | $66K | |
| 81025 | <1% | 1,825 | $65K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 675 | $60K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 457 | $59K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,208 | $57K |
| 83690 | <1% | 2,656 | $53K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,667 | $50K |
| 73630 | <1% | 645 | $50K | |
| 72110 | <1% | 436 | $50K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 116 | $49K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,989 | $48K |
| 93041 | <1% | 2,173 | $46K | |
| 73030 | <1% | 604 | $45K | |
| 82550 | <1% | 2,807 | $42K | |
| 83880 | <1% | 1,115 | $42K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,589 | $41K |
| 73610 | <1% | 488 | $38K | |
| 73564 | <1% | 417 | $37K | |
| 96376 | <1% | 1,247 | $34K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 747 | $31K |
| 87186 | <1% | 1,450 | $31K | |
| 73130 | <1% | 332 | $25K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 437 | $24K |
| 84703 | <1% | 1,091 | $23K | |
| 82652 | <1% | 781 | $23K | |
| 74018 | <1% | 303 | $22K | |
| 82746 | <1% | 757 | $22K | |
| 82803 | <1% | 508 | $21K | |
| 80074 | <1% | 275 | $20K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,287 | $19K |
| 84439 | <1% | 1,094 | $18K | |
| 84100 | <1% | 2,183 | $17K | |
| 87077 | <1% | 1,883 | $17K | |
| 82150 | <1% | 951 | $15K | |
| 71250 | <1% | 38 | $13K | |
| 85610 | <1% | 1,837 | $13K | |
| 87076 | <1% | 1,837 | $13K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 291 | $12K |
| 85730 | <1% | 688 | $11K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,302 | $11K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 51 | $10K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 826 | $10K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,207 | $10K |
| 94760 | <1% | 735 | $10K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 264 | $9K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 170 | $9K |
| 82043 | <1% | 880 | $8K | |
| 85378 | <1% | 357 | $8K | |
| 83540 | <1% | 625 | $7K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 43 | $7K |
| 73110 | <1% | 90 | $7K | |
| 36600 | <1% | 517 | $7K | |
| 85652 | <1% | 813 | $7K | |
| 84481 | <1% | 174 | $6K | |
| 87634 | <1% | 144 | $6K | |
| 82728 | <1% | 297 | $6K | |
| 86140 | <1% | 427 | $5K | |
| 85379 | <1% | 171 | $5K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 154 | $4K |
| 83550 | <1% | 308 | $4K | |
| 74022 | <1% | 31 | $4K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,133 | $4K |
| 82570 | <1% | 441 | $4K | |
| 84550 | <1% | 353 | $3K | |
| 84207 | <1% | 104 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 394 | $3K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 93 | $2K |
| 73502 | <1% | 37 | $2K | |
| 97161 | <1% | 53 | $2K | |
| 81002 | <1% | 132 | $2K | |
| 0002A | <1% | 195 | $2K | |
| 96367 | <1% | 33 | $1K | |
| 87522 | Neg quan hep c or qual rna | <1% | 40 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 487 | $1K |
| 72100 | <1% | 13 | $1K | |
| 97165 | <1% | 28 | $1K | |
| 80076 | <1% | 53 | $1K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 104 | $1K |
| 93225 | <1% | 29 | $1K | |
| 87070 | <1% | 60 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 558 | $1K |
| 73562 | <1% | 19 | $1K | |
| 0001A | <1% | 198 | $1K | |
| 86038 | <1% | 69 | $971.05 | |
| 97014 | <1% | 64 | $953.15 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 750 | $704.20 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 37 | $685.77 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 26 | $666.87 |
| 86308 | <1% | 43 | $666.10 | |
| 84436 | <1% | 64 | $655.72 | |
| 86803 | <1% | 46 | $610.20 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 74 | $458.96 |
| 84702 | <1% | 14 | $375.10 | |
| 86200 | <1% | 25 | $363.17 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 41 | $326.22 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 29 | $317.47 |
| 86431 | <1% | 33 | $241.13 | |
| 84479 | <1% | 28 | $212.31 | |
| 86756 | <1% | 13 | $196.88 | |
| 0012A | <1% | 25 | $139.09 | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 16 | $95.11 |
| 80143 | <1% | 12 | $85.65 | |
| 0011A | <1% | 19 | $85.45 | |
| 99406 | <1% | 18 | $65.68 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 78 | $62.50 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 17 | $5.01 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 14 | $2.02 |
| A9270 | Non-covered item or service | <1% | 100 | $0.97 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 57 | $0.04 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 23 | $0.02 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARRIS, HOLLIE (PRESIDENT AND CEO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.